Immune checkpoint inhibitor retreatment in second-line treatment of esophageal cancer: A real-world study.

被引：0
|
作者：
Kang, Yixin
Zhang, Dianbao
Mi, Youjia
Niu, Xiedong
Kang, Yuan
Xie, Dongjie
Li, Wenyao
Zhang, Ce
Yang, Junqiang
Yao, Jun
机构：
[1] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[2] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Gastroenterol Oncol, Luoyang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16034
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Second-Line Therapy for Immune Thrombocytopenia: Real-World Experience
    Nazaryan, Hasmik
    Liu, Yang
    Sirotich, Emily
    Duncan, Joanne M.
    Arnold, Donald M.
    BLOOD, 2019, 134
  • [2] Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor
    Yamazaki, Kentaro
    Yuki, Satoshi
    Oki, Eiji
    Sano, Fumikazu
    Makishima, Misako
    Aoki, Kenichi
    Hamano, Tetsutaro
    Yamanaka, Takeharu
    CLINICAL COLORECTAL CANCER, 2021, 20 (03) : E173 - E184
  • [3] US real-world ramucirumab and immune checkpoint inhibitor treatment sequences in advanced gastric, gastroesophageal junction, or esophageal cancer
    Liepa, A.
    Cui, Z.
    Beyrer, J.
    Hadden, E.
    Chatterjee, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S116 - S116
  • [4] Rate of patients receiving second-line treatment for metastatic colorectal cancer in a real-world setting
    Ups, Katherine
    Francesconi, Alessandra
    Ryan, Elizabeth G.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 114 - 114
  • [5] Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China
    Yang, Yang
    Tan, Lijie
    Hu, Jian
    Li, Yin
    Mao, Yousheng
    Tian, Ziqiang
    Zhang, Baihua
    Ma, Jianqun
    Li, Hecheng
    Chen, Chun
    Chen, Keneng
    Han, Yongtao
    Chen, Longqi
    Liu, Junfeng
    Yu, Bentong
    Yu, Zhentao
    Li, Zhigang
    DISEASES OF THE ESOPHAGUS, 2022, 35 (11)
  • [6] Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study.
    Santin, Alessandro
    Graf, Ryon
    Shah, Kunal J.
    Kelly, Andrew David
    Danziger, Natalie
    Lin, Douglas I.
    Oxnard, Geoffrey R.
    Elvin, Julia Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
    Barzi, Afsaneh
    Hess, Lisa M.
    Zhu, Yajun E.
    Liepa, Astra M.
    Sugihara, Tomoko
    Beyrer, Julie
    Chao, Joseph
    CANCER CONTROL, 2019, 26 (01)
  • [8] Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor
    Lin, Po -Ting
    Hsu, Yu -Chun
    Teng, Wei
    Hsieh, Yi-Chung
    Su, Chung-Wei
    Chai, Pei-Mei
    Lin, Chen-Chun
    Lin, Chun-Yen
    Lin, Shi-Ming
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (03):
  • [9] A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma
    Liu, Shaoxing
    Gao, Song
    Guo, Jianhai
    Kou, Fuxin
    Zhang, Xin
    Liu, Baojiang
    Feng, Aiwei
    Wang, Xiaodong
    Chen, Hui
    Zhu, Xu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] The real-world effectiveness of intravenous brivaracetam as a second-line treatment in status epilepticus
    Martellino, Chiara
    Lagana, Angelina
    Atanasio, Giorgia
    Lamanna, Fabio
    Attardo, Silvia
    Cascino, Simona
    De Luca, Marcella
    Pardeo, Orazio
    Giacobbe, Giuseppa
    Tripepi, Giovanni
    Roberti, Roberta
    Granata, Francesca
    Morace, Carmela
    Russo, Emilio
    Labate, Angelo
    EPILEPSY & BEHAVIOR, 2023, 148
12345